Peptides Might Be Making a Comeback In 2023, the FDA restricted 19 peptides from compounding pharmacies. Now, regulators are reviewing a possible reversal, which could allow 14 of those peptides to The Peptide Moment: How FDA's Regulatory Reversal Creates Risk and Opportunity for Venture Capital and Private Equity Guidepost Solutions Early evidence suggests BPC 157 repairs tissue rather than just dulling symptoms. To read more, tap the link in bio. The FDA has issued clear signals on BPC 157: it is not approved for human use in any form due to potential significant safety risks. This critical classification profoundly impacts research and